Pub Date : 2020-03-28DOI: 10.3760/CMA.J.CN115355-20190613-00250
R. Xu, Tao Yang, T. Xue, Tong-xin Yang
Objective To explore the value of tumor diameter to preoperative carcinoembryonic antigen (CEA) ratio (TCR) in predicting prognosis of patients with non-metastatic colorectal cancer. Methods The clinical data of 144 patients with colorectal cancer in Hainan Hospital of PLA General Hospital between July 2012 and December 2017 were retrospectively analyzed. Patients were divided into the low TCR group and the high TCR group according to the optimal value of TCR in predicting the disease-free survival (DFS) determined by the receiver operating characteristic curve (ROC). The clinicopathological features of both groups were analyzed, and the influencing factors of DFS were also analyzed by using Cox proportional hazard model. Results ROC analysis showed that TCR had a certain value in predicting DFS, and area under the curve (AUC) was 0.614 (95% CI 0.507-0.722); when the value of TCR was set at 0.690, the sensitivity and specificity of predicting the 3-year DFS rate was 46.3% and 70.9%, respectively. According to 0.690 of TCR, there were 50 cases in the low TCR ( 0.05). Univariate analysis showed that TCR, preoperative CEA level and TNM stage played a role in predicting DFS of patients (all P < 0.05), while Cox multivariate analysis indicated that TCR < 0.690 (HR = 2.369, 95% CI 1.279-4.388, P = 0.006) and Ⅲ stage in TNM stage (HR = 2.214, 95% CI 1.346-3.640, P = 0.002) were the independent risk factors of influencing DFS (all P < 0.01). The 3-year DFS rate of patients in the low TCR group was lower than that of those in the high TCR group (62.0% vs. 83.0%, P = 0.007). Conclusion TCR could have a certain value in judging the prognosis of non-metastatic colorectal cancer patients, and low TCR patients have a poorer prognosis. Key words: Colorectal neoplasms; Tumor diameter; Carcinoembryonic antigen; Disease-free survival; Prognosis
{"title":"Value of tumor diameter to preoperative carcinoembryonic antigen ratio in evaluating prognosis of non-metastatic colorectal cancer patients","authors":"R. Xu, Tao Yang, T. Xue, Tong-xin Yang","doi":"10.3760/CMA.J.CN115355-20190613-00250","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190613-00250","url":null,"abstract":"Objective \u0000To explore the value of tumor diameter to preoperative carcinoembryonic antigen (CEA) ratio (TCR) in predicting prognosis of patients with non-metastatic colorectal cancer. \u0000 \u0000 \u0000Methods \u0000The clinical data of 144 patients with colorectal cancer in Hainan Hospital of PLA General Hospital between July 2012 and December 2017 were retrospectively analyzed. Patients were divided into the low TCR group and the high TCR group according to the optimal value of TCR in predicting the disease-free survival (DFS) determined by the receiver operating characteristic curve (ROC). The clinicopathological features of both groups were analyzed, and the influencing factors of DFS were also analyzed by using Cox proportional hazard model. \u0000 \u0000 \u0000Results \u0000ROC analysis showed that TCR had a certain value in predicting DFS, and area under the curve (AUC) was 0.614 (95% CI 0.507-0.722); when the value of TCR was set at 0.690, the sensitivity and specificity of predicting the 3-year DFS rate was 46.3% and 70.9%, respectively. According to 0.690 of TCR, there were 50 cases in the low TCR ( 0.05). Univariate analysis showed that TCR, preoperative CEA level and TNM stage played a role in predicting DFS of patients (all P < 0.05), while Cox multivariate analysis indicated that TCR < 0.690 (HR = 2.369, 95% CI 1.279-4.388, P = 0.006) and Ⅲ stage in TNM stage (HR = 2.214, 95% CI 1.346-3.640, P = 0.002) were the independent risk factors of influencing DFS (all P < 0.01). The 3-year DFS rate of patients in the low TCR group was lower than that of those in the high TCR group (62.0% vs. 83.0%, P = 0.007). \u0000 \u0000 \u0000Conclusion \u0000TCR could have a certain value in judging the prognosis of non-metastatic colorectal cancer patients, and low TCR patients have a poorer prognosis. \u0000 \u0000 \u0000Key words: \u0000Colorectal neoplasms; Tumor diameter; Carcinoembryonic antigen; Disease-free survival; Prognosis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47865754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-28DOI: 10.3760/CMA.J.CN115355-20190618-00256
Kai Li, Q. Fu
High mobility group protein A2 (HMGA2) is a non-histone protein that does not have transcriptional activity by itself, but it changes its structure by binding to chromatin, which in turn regulates the transcription of other genes, thereby promoting tumor invasion and metastasis. The related RNA gene can regulate the role of HMGA2 in tumors, and the invasiveness of tumors is closely related to epithelial-mesenchymal transition (EMT), which can treat the related tumors by targeting HMGA2 gene. This article reviews the progress of the relationship between HMGA2 and tumors. Key words: High mobility group proteins; Molecular targeted therapy; RNA; Epithelial-mesenchymal transition
{"title":"Progress of the relationship between high mobility group protein A2 and tumors","authors":"Kai Li, Q. Fu","doi":"10.3760/CMA.J.CN115355-20190618-00256","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190618-00256","url":null,"abstract":"High mobility group protein A2 (HMGA2) is a non-histone protein that does not have transcriptional activity by itself, but it changes its structure by binding to chromatin, which in turn regulates the transcription of other genes, thereby promoting tumor invasion and metastasis. The related RNA gene can regulate the role of HMGA2 in tumors, and the invasiveness of tumors is closely related to epithelial-mesenchymal transition (EMT), which can treat the related tumors by targeting HMGA2 gene. This article reviews the progress of the relationship between HMGA2 and tumors. \u0000 \u0000 \u0000Key words: \u0000High mobility group proteins; Molecular targeted therapy; RNA; Epithelial-mesenchymal transition","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45217172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-28DOI: 10.3760/CMA.J.CN115355-20190814-00359
Xiaopan Li, Xi'an Lu
Papillary thyroid carcinoma is the most common malignant tumor in the head and neck. The incidence of papillary thyroid carcinoma has been increasing in recent years. Although the prognosis of most papillary thyroid carcinoma is better, many patients have poor prognosis due to recurrence or metastasis. Molecular markers play an important role in the development, diagnosis, treatment and prognosis of papillary thyroid carcinoma. This paper reviews the progress of molecular markers related to papillary thyroid carcinoma. Key words: Thyroid neoplasms; Carcinoma, papillary; Molecular markers; Prognosis; Treatment
{"title":"Progress of molecular markers related to papillary thyroid carcinoma","authors":"Xiaopan Li, Xi'an Lu","doi":"10.3760/CMA.J.CN115355-20190814-00359","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190814-00359","url":null,"abstract":"Papillary thyroid carcinoma is the most common malignant tumor in the head and neck. The incidence of papillary thyroid carcinoma has been increasing in recent years. Although the prognosis of most papillary thyroid carcinoma is better, many patients have poor prognosis due to recurrence or metastasis. Molecular markers play an important role in the development, diagnosis, treatment and prognosis of papillary thyroid carcinoma. This paper reviews the progress of molecular markers related to papillary thyroid carcinoma. \u0000 \u0000 \u0000Key words: \u0000Thyroid neoplasms; Carcinoma, papillary; Molecular markers; Prognosis; Treatment","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43595627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-28DOI: 10.3760/CMA.J.CN115355-20190515-00202
H. Ye, Xiao-xiang Yin, Ying Zhao, L. Gu
Objective To observe the efficacy of apatinib combined with capecitabine in the treatment of advanced esophageal cancer. Methods A total of 101 patients with advanced esophageal cancer in Taixing People's Hospital of Jiangsu Province from June 2017 to February 2018 were enrolled, and all the patients were divided into the control group (50 cases) and the observation group (51 cases) according to the random number table. The control group was treated with capecitabine combined with radiotherapy, and the observation group was treated with apatinib on the basis of the control group. The therapeutic effects, adverse reactions and progression-free survival (PFS) time of the two groups were compared. Results The overall response rate in the observation group was higher than that in the control group [90.2% (46/51) vs. 72.0% (36/50)], and the difference was statistically significant (χ2 = 5.473, P = 0.019). There were no significant differences in leukopenia, neutropenia, thrombocytopenia, anemia, proteinuria and hypertension between the two groups (all P > 0.05). The median PFS time in the observation group was 18.49 months (95% CI 15.35-25.03 months), and that in the control group was 13.33 months (95% CI 10.36-18.24 months), and the difference between the two groups was statistically significant (χ2 = 5.995, P < 0.01). Conclusions The therapeutic effect of apatinib combined with capecitabine in the treatment of advanced esophageal cancer is accurate. No obvious adverse reaction occurs, and the PFS time is prolonged. Key words: Esophageal neoplasms; Drug therapy, combination; Apatinib; Capecitabine
目的观察阿帕替尼联合卡培他滨治疗晚期食管癌的疗效。方法选取2017年6月~ 2018年2月在江苏省泰兴市人民医院住院治疗的晚期食管癌患者101例，按随机数字表法分为对照组(50例)和观察组(51例)。对照组给予卡培他滨联合放疗，观察组在对照组基础上给予阿帕替尼治疗。比较两组患者的治疗效果、不良反应及无进展生存期(PFS)。结果观察组总有效率高于对照组[90.2%(46/51)比72.0%(36/50)]，差异有统计学意义(χ2 = 5.473, P = 0.019)。两组患者白细胞减少、中性粒细胞减少、血小板减少、贫血、蛋白尿、高血压的发生率比较，差异均无统计学意义(P < 0.05)。观察组患者PFS中位时间为18.49个月(95% CI 15.35 ~ 25.03个月)，对照组患者PFS中位时间为13.33个月(95% CI 10.36 ~ 18.24个月)，两组比较差异有统计学意义(χ2 = 5.995, P < 0.01)。结论阿帕替尼联合卡培他滨治疗晚期食管癌疗效准确。无明显不良反应发生，PFS时间延长。关键词:食管肿瘤;药物治疗、联合用药;Apatinib;卡培他滨
{"title":"Efficacy observation of apatinib combined with capecitabine in the treatment of advanced esophageal cancer","authors":"H. Ye, Xiao-xiang Yin, Ying Zhao, L. Gu","doi":"10.3760/CMA.J.CN115355-20190515-00202","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190515-00202","url":null,"abstract":"Objective \u0000To observe the efficacy of apatinib combined with capecitabine in the treatment of advanced esophageal cancer. \u0000 \u0000 \u0000Methods \u0000A total of 101 patients with advanced esophageal cancer in Taixing People's Hospital of Jiangsu Province from June 2017 to February 2018 were enrolled, and all the patients were divided into the control group (50 cases) and the observation group (51 cases) according to the random number table. The control group was treated with capecitabine combined with radiotherapy, and the observation group was treated with apatinib on the basis of the control group. The therapeutic effects, adverse reactions and progression-free survival (PFS) time of the two groups were compared. \u0000 \u0000 \u0000Results \u0000The overall response rate in the observation group was higher than that in the control group [90.2% (46/51) vs. 72.0% (36/50)], and the difference was statistically significant (χ2 = 5.473, P = 0.019). There were no significant differences in leukopenia, neutropenia, thrombocytopenia, anemia, proteinuria and hypertension between the two groups (all P > 0.05). The median PFS time in the observation group was 18.49 months (95% CI 15.35-25.03 months), and that in the control group was 13.33 months (95% CI 10.36-18.24 months), and the difference between the two groups was statistically significant (χ2 = 5.995, P < 0.01). \u0000 \u0000 \u0000Conclusions \u0000The therapeutic effect of apatinib combined with capecitabine in the treatment of advanced esophageal cancer is accurate. No obvious adverse reaction occurs, and the PFS time is prolonged. \u0000 \u0000 \u0000Key words: \u0000Esophageal neoplasms; Drug therapy, combination; Apatinib; Capecitabine","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48194141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective To investigate the changes of serum thyroid hormone (TH) level in patients with breast cancer after radical mastectomy and its correlation with postoperative recurrence. Methods A total of 112 patients with breast cancer who underwent radical mastectomy in Hai'an People's Hospital of Jiangsu Province from January 2017 to January 2019 were selected as the breast cancer group, and 60 health examinees in the same period were selected as the control group. Serum thyroid stimulating hormone (TSH), free triiodothyronine (FT3), free tetraiodothyronine (FT4), total tetraiodothyronine (T4) Total triiodothyronine (T3) levels. Divide into recurrent group and non recurrent group based on postoperative recurrence, and compare the serum TH levels between the two groups. Results The preoperative serum T3, FT3 and FT4 levels [(1.58 ± 0.27) nmol/L, (4.42 ± 0.49) pmol/L, (9.68 ± 1.26) pmol/L] in the breast cancer group were lower than those in the control group [(2.05 ± 0.33) nmol/L, (4.94 ± 0.58) pmol/L, (11.17 ± 1.65) pmol/L] (all P<0.05). The postoperative serum T3, FT3 and FT4 levels [(1.96 ± 0.30) nmol/L, (4.75 ± 0.51) pmol/L, (10.52 ± 1.37) pmol/L] were all lower. It was higher than that before operation (all P<0.05). The serum levels of T3, FT3, and FT4 in TNM stage I patients were higher than those in stage II and III patients (all P<0.05), while the serum levels of T3, FT3, and FT4 in stage II patients were higher than those in stage III patients (all P<0.05). The preoperative serum T3, FT3 and FT4 levels in the non recurrence group of breast cancer patients were higher than those in the recurrence group (all P<0.05). Conclusion The levels of T3, FT3 and FT4 gradually decrease with the progression of the disease. After radical surgery for breast cancer, the clearing of the focus tissue causes the change of neurotransmitters, which leads to the increase of serum T3, FT3 and FT4 levels. The levels of T3, FT3 and FT4 in recurrent patients are lower than those in non recurrent patients. It is considered that the recurrence of breast cancer is related to thyroid dysfunction.
{"title":"Correlation of serum thyroid hormone level with recurrence in patients with breast cancer after radical mastectomy","authors":"Hai-bin Lu, Xiaozhong Ji","doi":"10.3760/CMA.J.CN115355-20190909-00408","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190909-00408","url":null,"abstract":"目的 \u0000探讨乳腺癌根治术后患者血清甲状腺激素（TH）水平变化及其与术后复发的相关性。 \u0000 \u0000 \u0000方法 \u0000选取2017年1月至2019年1月于江苏省海安市人民医院行乳腺癌根治术的患者112例为乳腺癌组，选取同期健康体检者60名为对照组，采用化学发光免疫法测定两组血清促甲状腺激素（TSH）、游离三碘甲状腺原氨酸（FT3）、游离四碘甲状腺原氨酸（FT4）、总四碘甲状腺原氨酸（T4）、总三碘甲状腺原氨酸（T3）水平。根据术后复发情况分为复发组和未复发组，比较两组血清TH水平。 \u0000 \u0000 \u0000结果 \u0000乳腺癌组术前血清T3、FT3及FT4水平[（1.58±0.27）nmol/L、（4.42±0.49）pmol/L、（9.68±1.26）pmol/L]均低于对照组[（2.05±0.33）nmol/L、（4.94±0.58）pmol/L、（11.17±1.65）pmol/L]（均P<0.05），术后血清T3、FT3及FT4水平[（1.96±0.30）nmol/L、（4.75±0.51）pmol/L、（10.52±1.37）pmol/L]均高于术前（均P<0.05）。TNM分期Ⅰ期患者血清T3、FT3及FT4水平高于Ⅱ、Ⅲ期患者（均P<0.05），Ⅱ期患者血清T3、FT3及FT4水平高于Ⅲ期患者（均P<0.05）。乳腺癌患者未复发组术前血清T3、FT3及FT4水平均高于复发组（均P<0.05）。 \u0000 \u0000 \u0000结论 \u0000T3、FT3及FT4水平随疾病进展进行性降低，乳腺癌根治术后由于病灶组织的清除引起神经递质的改变，从而导致血清T3、FT3及FT4水平的增加，复发患者T3、FT3及FT4水平低于未复发患者，考虑乳腺癌复发与甲状腺功能异常有关。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44278345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective To investigate the value of neutrophil-to-lymphocyte ratio (NLR) in the diagnosis and prognosis evaluation of primary hepatocellular carcinoma. Methods The clinical data of 100 patients pathologically diagnosed as primary liver cancer who were admitted to the First Medical Center of Chinese PLA General Hospital from January 2013 to December 2015 were retrospectively analyzed. Serum alpha fetoprotein (AFP), a conventional marker for hepatocellular carcinoma diagnosis was used as the control. The fourfold table diagnostic test was applied to analyze the sensitivity and specificity of serum NLR in the diagnosis of hepatocellular carcinoma, and the correlation with the degree of tumor differentiation was also analyzed. Results The proportion of patients with high NLR (≥1.70) [56% (56/100)] was higher than the proportion of patients with positive AFP [44% (44/100)] in all 100 hepatocellular carcinoma patients, but the difference was not statistically significant (χ2 = 2.88, P = 0.08). Among AFP-positive patients, the median survival time of patients with low and high NLR was 59 and 48 months, respectively, and the difference was statistically significant (χ2 = 3.91, P = 0.048), and high NLR was an independent risk factor affecting the prognosis of hepatocellular carcinoma patients (HR = 1.232, 95% CI 1.055-1.438, P = 0.008). Conclusions The detection of NLR combined with AFP can improve the diagnostic rate of hepatocellular carcinoma before surgery. High NLR is an independent risk factor affecting the prognosis of patients with primary hepatocellular carcinoma. Key words: Liver neoplasms; Neutrophil-to-lymphocyte ratio; Diagnosis; Prognosis
目的探讨中性粒细胞与淋巴细胞比值(NLR)在原发性肝癌诊断及预后评价中的价值。方法回顾性分析2013年1月至2015年12月解放军总医院第一医疗中心收治的100例经病理诊断为原发性肝癌患者的临床资料。血清甲胎蛋白(AFP)作为肝细胞癌诊断的常规标志物作为对照。应用四重表诊断试验分析血清NLR对肝细胞癌诊断的敏感性和特异性，并分析其与肿瘤分化程度的相关性。结果100例肝癌患者中，高NLR(≥1.70)患者比例[56%(56/100)]高于AFP阳性患者比例[44%(44/100)]，但差异无统计学意义(χ2 = 2.88, P = 0.08)。在afp阳性患者中，低NLR和高NLR患者的中位生存时间分别为59个月和48个月，差异有统计学意义(χ2 = 3.91, P = 0.048)，高NLR是影响肝细胞癌患者预后的独立危险因素(HR = 1.232, 95% CI 1.055 ~ 1.438, P = 0.008)。结论术前联合AFP检测NLR可提高肝癌的诊断率。高NLR是影响原发性肝癌患者预后的独立危险因素。关键词:肝脏肿瘤;Neutrophil-to-lymphocyte比率;诊断;预后
{"title":"Value of neutrophil-to-lymphocyte ratio in the diagnosis and prognosis evaluation of primary hepatocellular carcinoma","authors":"Yingwei Pan, XiangFei Meng, Lingyue Zhou, Zhiqiang Wang, Hangyu Zhang, Shi-xin Lu","doi":"10.3760/CMA.J.CN115355-20190906-00400","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190906-00400","url":null,"abstract":"Objective \u0000To investigate the value of neutrophil-to-lymphocyte ratio (NLR) in the diagnosis and prognosis evaluation of primary hepatocellular carcinoma. \u0000 \u0000 \u0000Methods \u0000The clinical data of 100 patients pathologically diagnosed as primary liver cancer who were admitted to the First Medical Center of Chinese PLA General Hospital from January 2013 to December 2015 were retrospectively analyzed. Serum alpha fetoprotein (AFP), a conventional marker for hepatocellular carcinoma diagnosis was used as the control. The fourfold table diagnostic test was applied to analyze the sensitivity and specificity of serum NLR in the diagnosis of hepatocellular carcinoma, and the correlation with the degree of tumor differentiation was also analyzed. \u0000 \u0000 \u0000Results \u0000The proportion of patients with high NLR (≥1.70) [56% (56/100)] was higher than the proportion of patients with positive AFP [44% (44/100)] in all 100 hepatocellular carcinoma patients, but the difference was not statistically significant (χ2 = 2.88, P = 0.08). Among AFP-positive patients, the median survival time of patients with low and high NLR was 59 and 48 months, respectively, and the difference was statistically significant (χ2 = 3.91, P = 0.048), and high NLR was an independent risk factor affecting the prognosis of hepatocellular carcinoma patients (HR = 1.232, 95% CI 1.055-1.438, P = 0.008). \u0000 \u0000 \u0000Conclusions \u0000The detection of NLR combined with AFP can improve the diagnostic rate of hepatocellular carcinoma before surgery. High NLR is an independent risk factor affecting the prognosis of patients with primary hepatocellular carcinoma. \u0000 \u0000 \u0000Key words: \u0000Liver neoplasms; Neutrophil-to-lymphocyte ratio; Diagnosis; Prognosis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44358476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-28DOI: 10.3760/CMA.J.CN115355-20190227-00056
Weigang Wang, Bao-guo Tian, Yan Wang
Breast cancer and thyroid diseases mostly occur in women, and both have seriously affected women's physical and mental health. Breast cancer patients have a higher risk of thyroid diseases before and after the onset of the disease compared with other malignant tumors. There are some common risk factors between them, and breast and thyroid are hormone-responsive organs, so they can also influence each other in some regulatory pathways. Iodine, thyroid hormone receptor and estrogen receptor are considered to be the possible pathogenesis of breast cancer. This paper explores the relationship between breast cancer and thyroid diseases with the help of researches in breast cancer, thyroid benign diseases, thyroid cancer, thyroid hormones and antibodies in recent years, so as to provide a basis for disease prevention and treatment. Key words: Breast neoplasms; Thyroid diseases; Thyroid hormone receptor; Estrogen receptor
{"title":"Progress of the relationship between breast cancer and thyroid diseases","authors":"Weigang Wang, Bao-guo Tian, Yan Wang","doi":"10.3760/CMA.J.CN115355-20190227-00056","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190227-00056","url":null,"abstract":"Breast cancer and thyroid diseases mostly occur in women, and both have seriously affected women's physical and mental health. Breast cancer patients have a higher risk of thyroid diseases before and after the onset of the disease compared with other malignant tumors. There are some common risk factors between them, and breast and thyroid are hormone-responsive organs, so they can also influence each other in some regulatory pathways. Iodine, thyroid hormone receptor and estrogen receptor are considered to be the possible pathogenesis of breast cancer. This paper explores the relationship between breast cancer and thyroid diseases with the help of researches in breast cancer, thyroid benign diseases, thyroid cancer, thyroid hormones and antibodies in recent years, so as to provide a basis for disease prevention and treatment. \u0000 \u0000 \u0000Key words: \u0000Breast neoplasms; Thyroid diseases; Thyroid hormone receptor; Estrogen receptor","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42904112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective To explore the cancer incidence and mortality in registration areas of Shanxi Province in 2014. Methods The data of 12 cancer registration areas of Shanxi Province in 2014 were taken to analyze the characteristics of cancer incidence and mortality for patients with different age and gender in different areas. And then the results were compared with the malignant cancer incidence and mortality in the nationwide. Results There were 11 703 new cases, including 6 559 males and 5 144 females in registration areas of Shanxi Province in 2014, and the incidence rate was 221.21/105, while the age-standardized incidence rate of Chinese population and world population was 163.91/105 and 163.25/105, respectively. The cancer incidence rate in urban areas was 247.02/105 and the age-standardized incidence rate of Chinese population was 171.35/105. In rural areas, the cancer incidence rate was 205.98/105 and the age-standardized incidence rate of Chinese population was 159.03/105. The common cancer sites were stomach, lung, esophagus, liver and colorectum for males. And breast, cervix, lung, esophagus, stomach were the common cancer sites for females. There were 7 283 malignant death cases, including 4 548 males and 2 735 females. The crude cancer mortality rate was 137.66/105, and the age-standardized mortality rate of Chinese population was 99.67/105 and world population was 100.11/105. The crude cancer mortality rate in urban areas was 141.03/105 and the age-standardized incidence rate of Chinese population was 92.84/105. In rural areas, the crude cancer mortality rate was 135.68/105 and the age-standardized mortality rate of Chinese population was 103.69/105. Male common malignant tumor deaths included lung cancer, gastric cancer, liver cancer, esophageal cancer and colorectal cancer, while lung, stomach, liver, esophagus and cervix were the common cancer death sites for females. Conclusions The incidence and mortality of malignant tumors in registration areas in Shanxi Province are mainly lung cancer, upper gastrointestinal cancer and cervix uteri cancer. The incidence rates of stomach cancer and cervical cancer are high. Key words: Malignant neoplasms; Incidence analysis; Mortality analysis; Cancer registry
{"title":"Analysis of cancer incidence and mortality in registration areas of Shanxi Province in 2014","authors":"Zhao-hui Ma, Q. Gao, Ling Cao, Xinzheng Wang, Xue-rong Guo, Xinchen Wang, Fang Su, N. Qiao, Yuan Wang, Ruifeng Zhang, Yong-zhen Zhang","doi":"10.3760/CMA.J.CN115355-20191030-00492","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20191030-00492","url":null,"abstract":"Objective \u0000To explore the cancer incidence and mortality in registration areas of Shanxi Province in 2014. \u0000 \u0000 \u0000Methods \u0000The data of 12 cancer registration areas of Shanxi Province in 2014 were taken to analyze the characteristics of cancer incidence and mortality for patients with different age and gender in different areas. And then the results were compared with the malignant cancer incidence and mortality in the nationwide. \u0000 \u0000 \u0000Results \u0000There were 11 703 new cases, including 6 559 males and 5 144 females in registration areas of Shanxi Province in 2014, and the incidence rate was 221.21/105, while the age-standardized incidence rate of Chinese population and world population was 163.91/105 and 163.25/105, respectively. The cancer incidence rate in urban areas was 247.02/105 and the age-standardized incidence rate of Chinese population was 171.35/105. In rural areas, the cancer incidence rate was 205.98/105 and the age-standardized incidence rate of Chinese population was 159.03/105. The common cancer sites were stomach, lung, esophagus, liver and colorectum for males. And breast, cervix, lung, esophagus, stomach were the common cancer sites for females. There were 7 283 malignant death cases, including 4 548 males and 2 735 females. The crude cancer mortality rate was 137.66/105, and the age-standardized mortality rate of Chinese population was 99.67/105 and world population was 100.11/105. The crude cancer mortality rate in urban areas was 141.03/105 and the age-standardized incidence rate of Chinese population was 92.84/105. In rural areas, the crude cancer mortality rate was 135.68/105 and the age-standardized mortality rate of Chinese population was 103.69/105. Male common malignant tumor deaths included lung cancer, gastric cancer, liver cancer, esophageal cancer and colorectal cancer, while lung, stomach, liver, esophagus and cervix were the common cancer death sites for females. \u0000 \u0000 \u0000Conclusions \u0000The incidence and mortality of malignant tumors in registration areas in Shanxi Province are mainly lung cancer, upper gastrointestinal cancer and cervix uteri cancer. The incidence rates of stomach cancer and cervical cancer are high. \u0000 \u0000 \u0000Key words: \u0000Malignant neoplasms; Incidence analysis; Mortality analysis; Cancer registry","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42992343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-28DOI: 10.3760/CMA.J.CN115355-20190623-00265
Linghua Meng, Hai-Zhi Wu, T. Liang
Microsatellite instability (MSI) is caused by the deficiency of DNA mismatch repair (MMR) protein, which is closely related to the occurrence, development, prognosis and efficacy prediction of various tumors. MSI-high (MSI-H) and mismatch repair protein deficiency (dMMR) might be a predictor factor for the good prognosis of patients with gastric cancer, and a negative predictor factor for the chemotherapy efficacy of resectable gastric cancer. MSI-H/dMMR can be used as a marker for predicting the effective treatment outcome of immune checkpoint inhibitors in advanced gastric cancer, however, the predictive role in palliative chemotherapy of advanced gastric cancer is still unclear. This paper reviews the progress of the association of MSI/MMR with prognosis and efficacy prediction in gastric cancer. Key words: Stomach neoplasms; Microsatellite instability; Mismatch repair protein; Prognosis; Efficacy prediction
{"title":"Significance of microsatellite instability for the prognosis and efficacy prediction in gastric cancer","authors":"Linghua Meng, Hai-Zhi Wu, T. Liang","doi":"10.3760/CMA.J.CN115355-20190623-00265","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190623-00265","url":null,"abstract":"Microsatellite instability (MSI) is caused by the deficiency of DNA mismatch repair (MMR) protein, which is closely related to the occurrence, development, prognosis and efficacy prediction of various tumors. MSI-high (MSI-H) and mismatch repair protein deficiency (dMMR) might be a predictor factor for the good prognosis of patients with gastric cancer, and a negative predictor factor for the chemotherapy efficacy of resectable gastric cancer. MSI-H/dMMR can be used as a marker for predicting the effective treatment outcome of immune checkpoint inhibitors in advanced gastric cancer, however, the predictive role in palliative chemotherapy of advanced gastric cancer is still unclear. This paper reviews the progress of the association of MSI/MMR with prognosis and efficacy prediction in gastric cancer. \u0000 \u0000 \u0000Key words: \u0000Stomach neoplasms; Microsatellite instability; Mismatch repair protein; Prognosis; Efficacy prediction","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44475614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-03-28DOI: 10.3760/CMA.J.CN115355-20190509-00191
Lili Liu, B. Chang, Haiyi Liu, Yixun Zhang, Maoxin Liu, Li-chun Wang, Haibo Wang
Objective To investigate the significance of changes of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in neoadjuvant therapy for rectal cancer. Methods The data of 86 patients with rectal cancer who received neoadjuvant therapy from November 2013 to January 2015 in Shanxi Provincial Cancer Hospital were retrospectively analyzed, and the correlations of NLR and PLR changes with the patients' clinicopathological characteristics and therapeutic effects were also analyzed. Results There were 43 cases of increased NLR and 43 cases of increased PLR after treatment. NLR and PLR changes before and after neoadjuvant therapy in patients with rectal cancer were not associated with age, gender, TNM stage, lymph node metastasis, number of cancer nodules, and tumor diameter (all P > 0.05). The increasing proportion of NLR and PLR after treatment in patients with the distance from the tumor to anus 0.05). Conclusion NLR changes are associated with therapeutic efficacy before and after neoadjuvant therapy for patients with rectal cancer. Key words: Rectal neoplasms; Neutrophil-to-lymphocyte ratio; Platelet-to-lymphocyte ratio; Neoadjuvant therapy
{"title":"Significance of changes of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in neoadjuvant therapy for rectal cancer","authors":"Lili Liu, B. Chang, Haiyi Liu, Yixun Zhang, Maoxin Liu, Li-chun Wang, Haibo Wang","doi":"10.3760/CMA.J.CN115355-20190509-00191","DOIUrl":"https://doi.org/10.3760/CMA.J.CN115355-20190509-00191","url":null,"abstract":"Objective \u0000To investigate the significance of changes of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in neoadjuvant therapy for rectal cancer. \u0000 \u0000 \u0000Methods \u0000The data of 86 patients with rectal cancer who received neoadjuvant therapy from November 2013 to January 2015 in Shanxi Provincial Cancer Hospital were retrospectively analyzed, and the correlations of NLR and PLR changes with the patients' clinicopathological characteristics and therapeutic effects were also analyzed. \u0000 \u0000 \u0000Results \u0000There were 43 cases of increased NLR and 43 cases of increased PLR after treatment. NLR and PLR changes before and after neoadjuvant therapy in patients with rectal cancer were not associated with age, gender, TNM stage, lymph node metastasis, number of cancer nodules, and tumor diameter (all P > 0.05). The increasing proportion of NLR and PLR after treatment in patients with the distance from the tumor to anus 0.05). \u0000 \u0000 \u0000Conclusion \u0000NLR changes are associated with therapeutic efficacy before and after neoadjuvant therapy for patients with rectal cancer. \u0000 \u0000 \u0000Key words: \u0000Rectal neoplasms; Neutrophil-to-lymphocyte ratio; Platelet-to-lymphocyte ratio; Neoadjuvant therapy","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44260820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：